Tech Transfer eNews Blog

University consortium licenses more than 200 antibodies


By Jesse Schwartz
Published: December 4th, 2019

Absolute Antibody, a leading provider of recombinant antibody products and services, has partnered with the Recombinant Antibody Network (RAN) in a licensing deal that will make university-developed antibodies available to a wider scientific audience.

RAN is a consortium of three antibody research centers at the University of Chicago, the University of Toronto and the University of San Francisco, aimed at generating recombinant antibodies at a proteome-wide scale. Under the new partnership with Absolute Antibody, select RAN antibodies will be engineered into new formats and promoted via Absolute’s online reagents catalog, where researchers worldwide can easily access them for experiments in chromatin biology, infectious disease control, and other fields.

“We’re excited to partner with the Recombinant Antibody Network, which has been visionary in its efforts to generate a comprehensive set of recombinant antibodies for biomedical research,” says Amelia Gibson, director of business development at Absolute Antibody. “The Network shares our mission to further the availability of recombinant antibodies to advance scientific research, and we’re eager to bring this valuable collection of antibodies to a wider audience in newly engineered formats,” Gibson adds.

The sequences and validation data for more than 200 antibodies directed to intracellular targets generated by RAN have been licensed to Absolute Antibody by the University of Chicago’s Polsky Center for Entrepreneurship and Innovation on behalf of the RAN members.

Anthony Kossiakoff, professor at UChicago and co-founder of RAN, comments, “Our new partnership with Absolute Antibody significantly extends the reach of the recombinant antibodies developed at our three university sites. Our consortium is committed to generating and validating functional antibodies for protein targets across the human proteome, and by partnering with Absolute Antibody, these antibodies will reach scientists worldwide for use in new applications, to further their contribution to scientific progress.”

Source: Markets Insider

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment